Prognostic value, immune signature and molecular mechanisms of the SUMO family in pancreatic adenocarcinoma

Background: Pancreatic adenocarcinoma (PAAD) has a high degree of malignancy and a very poor prognosis, and the 5-year overall survival rate of patients is approximately 7%. To improve the prognosis of patients with PAAD, a more comprehensive and in-depth study of the pathogenesis of PAAD and the identification of new diagnostic markers and treatment targets are urgently needed. Increasing evidence supports that the small ubiquitin-like modifier (SUMO) family is closely related to the occurrence and development of a variety of cancers. However, the function of the SUMO family in PAAD is not clear, and related research is very scarce. Methods: R, Cytoscape, cBioPortal, and other software and online databases were used to comprehensively analyze the expression characteristics, prognostic value, and oncogenic mechanism of the SUMO family in PAAD. Results: SUMO family members are highly expressed in PAAD, and high expression of SUMO family members is significantly associated with poor clinicopathological features and poor prognosis in PAAD patients. In addition, SUMO family members are significantly coexpressed with M6A methylation regulators and various oncogenes and play an activating role in various oncogenic pathways, including EMT. Furthermore, it is worth noting that the close association between SUMO family members and TP53 mutation status and the negative regulatory effect of SUMO1/2 on PAAD immunity may represent the potential mechanism by which SUMO family members promote the development of PAAD. Moreover, the coexpression characteristics of SUMO family members and a variety of cancer-promoting immune checkpoint genes, as well as the positive correlation between SUMO4 expression level and the sensitivity of various targeted or chemotherapeutic drugs, including gemcitabine, paclitaxel, and doxorubicin, suggest future clinical directions of this study. Conclusion: The SUMO family is closely related to the occurrence and development of PAAD and can be used as a new biomarker and therapeutic target for patients with PAAD.

[1]  Yongxing Du,et al.  Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma , 2022, International journal of molecular sciences.

[2]  Stephen L. Abrams,et al.  Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression , 2022, Cells.

[3]  Xueqi Fan,et al.  Disease Burden of Pancreatic Cancer — China, 1990−2019 , 2022, China CDC weekly.

[4]  Jia Song,et al.  Calpain2 Upregulation Regulates EMT-Mediated Pancreatic Cancer Metastasis via the Wnt/β-Catenin Signaling Pathway , 2022, Frontiers in Medicine.

[5]  Chun-Fang Xu,et al.  Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China , 2022, World journal of clinical cases.

[6]  Chengfeng Wang,et al.  Expression, Prognostic Value, and Functional Mechanism of the KDM5 Family in Pancreatic Cancer , 2022, Frontiers in Cell and Developmental Biology.

[7]  V. Passos,et al.  The increasing burden of pancreatic cancer in Brazil from 2000 to 2019: estimates from the Global Burden of Disease Study 2019. , 2022, Revista da Sociedade Brasileira de Medicina Tropical.

[8]  Mengchun Li,et al.  MiR-451a promotes cell growth, migration and EMT in osteosarcoma by regulating YTHDC1-mediated m6A methylation to activate the AKT/mTOR signaling pathway , 2022, Journal of bone oncology.

[9]  Wei Huang,et al.  Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer , 2021, Frontiers in Cell and Developmental Biology.

[10]  I. Bednarek,et al.  Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis , 2021, Cells.

[11]  B. Baradaran,et al.  The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment , 2021, International journal of molecular sciences.

[12]  Hassam Ali,et al.  Pancreatic cancer incidence trends in the United States from 2000-2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database , 2021, F1000Research.

[13]  A. Lánczky,et al.  Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation , 2021, Journal of medical Internet research.

[14]  Yancheng Jiang,et al.  Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion , 2021, FEBS open bio.

[15]  Jiguang Meng,et al.  LncRNA SNHG3 Promotes Proliferation and Metastasis of Non-Small-Cell Lung Cancer Cells Through miR-515-5p/SUMO2 Axis , 2021, Technology in cancer research & treatment.

[16]  H. Ford,et al.  VEGF-C Mediates Tumor Growth and Metastasis Through Promoting EMT- Epithelial Breast Cancer cell Crosstalk , 2020, Oncogene.

[17]  A. Neri,et al.  Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? , 2020, Frontiers in Oncology.

[18]  J. Huse,et al.  YTHDF3 Induces the Translation of m6A-Enriched Gene Transcripts to Promote Breast Cancer Brain Metastasis. , 2020, Cancer cell.

[19]  Joon-Oh Park,et al.  Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions , 2020, Genome medicine.

[20]  P. Ma,et al.  Ephrin-A2 promotes prostate cancer metastasis by enhancing angiogenesis and promoting EMT , 2020, Journal of Cancer Research and Clinical Oncology.

[21]  Chuan He,et al.  Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer , 2020, Molecular Cancer.

[22]  Xiaoshun He,et al.  YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation , 2020, Oncogene.

[23]  Ligong Lu,et al.  SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma , 2020, Theranostics.

[24]  Jianxun Song,et al.  Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma , 2020, Molecular Cancer.

[25]  Fang Wang,et al.  The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation , 2020, Nucleic acids research.

[26]  G. Velasco,et al.  Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1 , 2019, Journal of Cell Science.

[27]  Beibei Ru,et al.  TISIDB: an integrated repository portal for tumor-immune system interactions , 2019, Bioinform..

[28]  Lin Lin,et al.  m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. , 2019, American journal of translational research.

[29]  Haiyang Xie,et al.  WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1 , 2019, Molecular Cancer.

[30]  D. Lin,et al.  METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma , 2019, Molecular Cancer.

[31]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[32]  Xiaofei Li,et al.  SUMO1 promotes the proliferation and invasion of non‐small cell lung cancer cells by regulating NF‐κB , 2018, Thoracic cancer.

[33]  Qiong Zhang,et al.  GSCALite: a web server for gene set cancer analysis , 2018, Bioinform..

[34]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[35]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[36]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[37]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[38]  Chuan He,et al.  m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. , 2017, Cancer cell.

[39]  Kexin Shen,et al.  SUMO-1 Gene Silencing Inhibits Proliferation and Promotes Apoptosis of Human Gastric Cancer SGC-7901 Cells , 2017, Cellular Physiology and Biochemistry.

[40]  G. Ichim,et al.  A fate worse than death: apoptosis as an oncogenic process , 2016, Nature Reviews Cancer.

[41]  Kaori Takai,et al.  RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated. , 2016, Cancer letters.

[42]  J. Potter,et al.  Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. , 2015, JAMA oncology.

[43]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[44]  J. Olson,et al.  SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression , 2014, Nature Communications.

[45]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[46]  W. Paschen,et al.  Small ubiquitin‐like modifier 1–3 is activated in human astrocytic brain tumors and is required for glioblastoma cell survival , 2013, Cancer science.

[47]  P. Bork,et al.  A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL , 2012, British journal of haematology.

[48]  N. Nan,et al.  [Association between SUMO4 polymorphisms and type 2 diabetes mellitus]. , 2012, Yi chuan = Hereditas.

[49]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[50]  K. Stoeber,et al.  The cell cycle and cancer , 2012, The Journal of pathology.

[51]  Akira Mogi,et al.  TP53 Mutations in Nonsmall Cell Lung Cancer , 2011, Journal of biomedicine & biotechnology.

[52]  K. Vähäkangas,et al.  p53 in head and neck cancer: Functional consequences and environmental implications of TP53 mutations , 2010, Head & neck oncology.

[53]  Edward T H Yeh,et al.  SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. , 2010, Genes & cancer.

[54]  J. She,et al.  SUMO4 and its role in type 1 diabetes pathogenesis , 2008, Diabetes/metabolism research and reviews.

[55]  P. Shannon,et al.  Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks , 2003 .

[56]  Jun S. Liu,et al.  TIMER : AWeb Server for Comprehensive Analysis of Tumor-In fi ltrating Immune Cells , 2017 .

[57]  A. Børresen-Dale,et al.  TP53 Mutations in Breast and Ovarian Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[58]  Magali Olivier,et al.  TP53 mutations in human cancers: origins, consequences, and clinical use. , 2010, Cold Spring Harbor perspectives in biology.

[59]  M. Goggins,et al.  Epigenetics and epigenetic alterations in pancreatic cancer. , 2009, International journal of clinical and experimental pathology.

[60]  Christian von Mering,et al.  STRING: a database of predicted functional associations between proteins , 2003, Nucleic Acids Res..